[Serum adiponectin level in patients of chronic pulmonary heart disease with cardiac failure].
To investigate the changes of the concentration of serum adiponectin in patients of chronic pulmonary heart disease (CPHD) with cardiac failure. Thirty-eight CPHD patients with cardiac failure underwent conventional treatment, and were divided into 2 subgroups: remission subgroup (n = 32) and non-remission subgroup (n = 6) according to the therapeutic effects 2 weeks later. Peripheral blood samples were collected from these 38 CPHD patients (CPHD group), including the remission subgroup and non-remission subgroup, and 30 healthy persons (as normal control group). Enzyme linked immunosorbent assay (ELISA) was used to detect the serum levels of adiponectin, interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha before and 2 weeks after treatment. The serum adiponectin of the CPHD group was (9.5 +/- 7.1) ng/L in general, significantly lower than that of the normal control group [(21.5 +/- 9.0) ng/L, P < 0.01]. The serum adiponectin of the remission group was (17.0 +/- 6.3) ng/L, significantly higher than that of the non-remission group [(8.1 +/- 4.8) ng/L, P < 0.01], but still significantly lower than that of the normal control group (P < 0.05). The IL-6 and TNF-alpha levels of the CPHD group were (50.0 +/- 17.6) and (53.8 +/- 16.2) ng/L respectively, both significantly higher than those of normal control group [(24.4 +/- 9.1) and (28.4 +/- 11.4) ng/L respectively, both P < 0.01]. The IL-6 and TNF-alpha levels of the remission group were (29.0 +/- 12.1) ng/L and (32.3 +/- 13.5) ng/L respectively, both significantly lower than those of the non-remission group [(56.0 +/- 16.0) and (59.3 +/- 19.1) ng/L respectively, both P < 0.01], but not significantly different from those of the normal control group. There were no significant differences in the adiponectin, IL-6, and TNF-alpha levels between the non-remission group and the CPHD group. Adiponectin is involved in the pathophysiological process of heart failure in the CPHD patients. It may be a useful index to guide treatment and judge prognosis by dynamically determining the serum adiponectin.